Connecting Science and Business No. 2/2006
New Name
Garching Innovation Became Max Planck Innovation
For several decades, technology transfer at the Max Planck Society has been associated with the town of Garching, originally as Garching Instrumente - Gesellschaft zur industriellen Nutzung von Forschungsergebnissen mbH then from 1993 onwards as "Garching Innovation“ with the recent addition: "Technologies from the Max Planck Society". continue
Latest technology offers from all areas
High efficiency hydrodynamic collimation vacuum interface for atmospheric pressure ion sources (20.04.2012)
Vorrichtung zur Zuführung eines flüssigen Gases in ein Gefäß – Tube Extension for Transfer of Liquid Gases (16.04.2012)
Dual-Mode Microwave Resonator for Double Electron Spin Resonance Spectroscopy (12.04.2012)
Success Stories
Max Planck Innovation can look back at a number of very successful technology transfer projects over the past 35 years. Max Planck Innovation has managed about 2,600 inventions and closed more than 1,550 licensing agreements; the total proceeds for inventors, Max Planck Institutes and Max Planck Society amount to about €200m. continue
FLASH – a Technology Revolution in Diagnostics
Whoever applies for a patent must be prepared for conflict. This lesson was learned from the so-called FLASH patent filed in February 1985 by scientists Prof. Jens Frahm and Prof. Axel Haase together with Dr Wolfgang Hänicke, Dr Klaus-Dietmar Merboldt and Dr Dieter Matthaei from the Max Planck Institute for Biophysical Chemistry, with the support of Garching Innovation, now Max Planck Innovation. The patent expired in February 2006 and with license fees of about €150m in total, it has been the most lucrative patent for Max Planck Innovation to date. continue
Sutent® – A Novel Drug Gives Hope to Cancer Patients
Molecular biology inventions are among the potentially most lucrative licensing opportunities. But in addition, the risk of failure is nowhere as high and the way to a final product nowhere as long – at least as far as novel targets are concerned, i.e. potential starting points for the development of drugs. It may take 12 to 15 years until the discovery of a target – a novel receptor, an enzyme, or a new pathway – leads to a marketable, approved drug. continue
Max Planck Society Spin-off Profile
MenloSystems GmbH – Measuring with Unprecedented Precision
Scientists interested in founding a company are soon confronted with the question of how to obtain seed capital. High-tech spinout companies of the Max Planck Society usually look for venture capital. But this is not always the best way forward. continue
Frequently Asked Questions
Can Software Be Patented?
Dr. Niels Hölder, Axel Stellbrink and Rainer Viktor, Vossius & Partner Patent Attorneys and Attorneys-at-Law, Munich
Despite rumours in the scientific community software can be protected by patents, if it involves a technical character, such as a technical effect, a technical problem to be solved, technical features or considerations. The advantages and prerequisites of patent protection for software are briefly discussed in the following. continue
All the best,
your Max-Planck-Innovation team
Latest events
14.06.2012
15.06.2012
Please save the date! – 2nd Founders Academy
18.06.2012
22.06.2012
ACHEMA 2012 | Frankfurt
02.07.2012
06.07.2012
15th International Congress on Catalysis 2012 | Munich
Recent spotlights
20.03.2012
SCIENION introduces sciREADER CL for colorimetric detection of multiplex assays. More
19.03.2012
Alnylam Initiates Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). More
15.03.2012
Protagen and NMI announce Co-Development of Multiplex Assays. More
Subscribe / unsubscribe the newsletter
Would you like to receive or cancel our press relaeses or newsletter?
Please click here
Media contacts
Evelyn Wolf
Phone: (089) 4445 2099
Astrid Giegold
Phone: (089) 2909 1911